Document is current
Any future updates will be listed below
-
Authors
Flayer, Cameron H. http://orcid.org/0000-0002-3001-9058
Kernin, Isabela J.
Matatia, Peri R. http://orcid.org/0000-0002-5389-3637
Zeng, Xiangsunze
Yarmolinsky, David A.
Han, Cai
Naik, Parth R. http://orcid.org/0009-0003-0385-4597
Buttaci, Dean R.
Aderhold, Pamela A.
Camire, Ryan B.
Zhu, Xueping
Tirard, Alice J.
McGuire, John T.
Smith, Neal P. http://orcid.org/0000-0003-1394-3158
McKimmie, Clive S. http://orcid.org/0000-0002-7694-9509
McAlpine, Cameron S. http://orcid.org/0000-0002-9832-6345
Swirski, Filip K. http://orcid.org/0000-0002-3163-9152
Woolf, Clifford J. http://orcid.org/0000-0002-6636-3897
Villani, Alexandra-Chloe http://orcid.org/0000-0001-7461-0408
Sokol, Caroline L. http://orcid.org/0000-0003-0473-7555
- License Information
-
More Information
Article History
Received: 19 January 2023
Accepted: 23 July 2024
First Online: 4 September 2024
Competing interests
: C.L.S. is a paid consultant for Bayer and Merck and receives sponsored research support from GSK. P.A.A. is a current employee of Werewolf Therapeutics. C. S. McAlpine is a paid consultant of Granite Bio. C.J.W. is a founder of Nocion Therapeutics, QurAlis and BlackBox Bio, and is on the scientific advisory board of Lundbeck Pharma, Axonis and Tafalgie Therapeutics. A.-C.V. has a financial interest in 10X Genomics. The company designs and manufactures gene sequencing technology for use in research, and such technology is being used in this research. A.-C.V.’s interests were reviewed by The Massachusetts General Hospital and Mass General Brigham in accordance with their institutional policies.
